.
MergerLinks Header Logo

Announced

Completed

SomaLogic went public via merger with CM Life Sciences II in a $1.2bn deal.

Financials

Edit Data
Transaction Value£891m
Consideration TypeCash
Capital Owned-
Capital Bid For100%
EV/Sales-
EV/EBITDA-
Share Price Premium-
One Off Charge-

Tags

Edit

Domestic

Reverse Takeover

De-SPAC

Private Equity

Single Bidder

Biotechnology

Private

United States

proteomics

Acquisition

Merger

Friendly

Completed

Synopsis

Edit

SomaLogic, a proteomics technology company, went public via merger with CM Life Sciences II, a special purpose acquisition company sponsored by affiliates of Casdin Capital and Corvex Management, in a $1.2bn deal. The transaction included a fully committed PIPE of $375m from Casdin Capital, Corvex Management, Janus Henderson Investors, SoftBank, T.Rowe Price, ARK Invest, Farallon Capital, Perceptive Advisors, Morgan Stanley, Illumina, Soleus, Foresite and Novartis Pharma. "This is a powerful business combination for SomaLogic that will bring significant capital and intellectual resources to propel the next chapter of the company’s growth," Roy Smythe, SomaLogic CEO.

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US